Precision Biosciences Capital Raise
Precision BioSciences provided an update on its previously announced public offering of 10,235,077 shares of common stock and 5,893,964 pre-funded warrants. The company expects the net proceeds to extend its cash runway into the fourth quarter of 2029, providing sufficient capital to fund its PBGENE-HBV and PBGENE-DMD clinical programs through key inflection points.